Robert Carroll1, Alison Mudge2, Jessica Suna3, Charles Denaro2, John Atherton4. 1. Department of Internal Medicine and Aged Care, Royal Brisbane and Women's Hospital, Butterfield St., Herston, Qld 4006, Australia; University of Queensland School of Medicine, 288 Herston Road, Qld 4006, Australia. Electronic address: robert.carroll@uqconnect.edu.au. 2. Department of Internal Medicine and Aged Care, Royal Brisbane and Women's Hospital, Butterfield St., Herston, Qld 4006, Australia; University of Queensland School of Medicine, 288 Herston Road, Qld 4006, Australia. 3. Department of Internal Medicine and Aged Care, Royal Brisbane and Women's Hospital, Butterfield St., Herston, Qld 4006, Australia. 4. University of Queensland School of Medicine, 288 Herston Road, Qld 4006, Australia; Department of Cardiology, Royal Brisbane and Women's Hospital, Butterfield St., Herston, Qld 4006, Australia.
Abstract
BACKGROUND: Heart failure (HF) medications improve clinical outcomes, with optimal doses defined in clinical trials. Patient, provider and system barriers may limit achievement of optimal doses in real life settings, although disease management programs (HF-DMPs) can facilitate up-titration. METHODS AND RESULTS: Secondary analysis of a prospective cohort of 216 participants recently hospitalized with systolic HF, attending 5 HF-DMPs in Queensland, Australia. Medication history at baseline (6weeks after discharge) and 6months provided data to describe prescription rates, dosage and optimal titration of HF medications, and associations with patient and system factors were explored. At baseline, 94% were on an angiotensin converting enzyme inhibitor/angiotensin II receptor blocker (ACEI/ARB), 94% on a beta-blocker (BB) and 42% on a mineralocorticoid receptor antagonist (MRA). The proportion of participants on optimal doses of ACEI/ARB increased from 38% (baseline) to 52% (6months, p=0.001) and on optimal BB dose from 23% to 49% (p<0.001). Significant barriers to ACEI/ARB up-titration were body mass index (BMI)<25, female gender, polypharmacy, previously diagnosed HF, and tertiary hospital. Significant barriers for BB up-titration were BMI<25, previously diagnosed HF and non-cardiologist care. CONCLUSIONS: Effective up-titration in HF DMPs is influenced by patient, disease and service factors. Better understanding of barriers to effective up-titration in women, normal weight, and established HF patients may help provide targeted strategies for improving outcomes in these groups.
BACKGROUND:Heart failure (HF) medications improve clinical outcomes, with optimal doses defined in clinical trials. Patient, provider and system barriers may limit achievement of optimal doses in real life settings, although disease management programs (HF-DMPs) can facilitate up-titration. METHODS AND RESULTS: Secondary analysis of a prospective cohort of 216 participants recently hospitalized with systolic HF, attending 5 HF-DMPs in Queensland, Australia. Medication history at baseline (6weeks after discharge) and 6months provided data to describe prescription rates, dosage and optimal titration of HF medications, and associations with patient and system factors were explored. At baseline, 94% were on an angiotensin converting enzyme inhibitor/angiotensin II receptor blocker (ACEI/ARB), 94% on a beta-blocker (BB) and 42% on a mineralocorticoid receptor antagonist (MRA). The proportion of participants on optimal doses of ACEI/ARB increased from 38% (baseline) to 52% (6months, p=0.001) and on optimal BB dose from 23% to 49% (p<0.001). Significant barriers to ACEI/ARB up-titration were body mass index (BMI)<25, female gender, polypharmacy, previously diagnosed HF, and tertiary hospital. Significant barriers for BB up-titration were BMI<25, previously diagnosed HF and non-cardiologist care. CONCLUSIONS: Effective up-titration in HF DMPs is influenced by patient, disease and service factors. Better understanding of barriers to effective up-titration in women, normal weight, and established HF patients may help provide targeted strategies for improving outcomes in these groups.
Authors: Michael J Diamant; Sean A Virani; Winston J MacKenzie; Andrew Ignaszewski; Mustafa Toma; Nathaniel M Hawkins Journal: ESC Heart Fail Date: 2019-06-20
Authors: Alexander J Blood; Christina M Fischer; Liliana E Fera; Taylor E MacLean; Katelyn V Smith; Jacqueline R Dunning; Joshua W Bosque-Hamilton; Samuel J Aronson; Thomas A Gaziano; Calum A MacRae; Lina S Matta; Ana A Mercurio-Pinto; Shawn N Murphy; Benjamin M Scirica; Kavishwar Wagholikar; Akshay S Desai Journal: Clin Cardiol Date: 2019-11-14 Impact factor: 2.882
Authors: Kannan O Ahmed; Imad Taj Eldin; Mirghani Yousif; Ahmed A Albarraq; Bashir A Yousef; Nasrein Ahmed; Anas Babiker Journal: Integr Pharm Res Pract Date: 2021-11-11
Authors: Kenneth D Varian; Xinge Ji; Justin L Grodin; Frederik H Verbrugge; Alex Milinovich; Michael W Kattan; W H Wilson Tang Journal: ESC Heart Fail Date: 2020-08-05
Authors: Clare J Taylor; José M Ordóñez-Mena; Nicholas R Jones; Andrea K Roalfe; Sarah Lay-Flurrie; Tom Marshall; F D Richard Hobbs Journal: Eur J Heart Fail Date: 2020-09-23 Impact factor: 17.349